CIBMTR Real-World Outcomes of Older Patients Treated with Idecabtagene Vicleucel (IMS 2026) - Sep 11, 2026 - Abstract #PA-078; Pres time: Sep 24, 2026; "With extended follow-up, ide-cel effectiveness (ORR, PFS), as well as safety, was broadly comparable across age groups, albeit with numerically higher treatment-related mortality in older patients. Findings are directionally consistent with 6-mo outcomes reported for an earlier data cut and continue to highlight the benefit of ide-cel in older pts who may typically be overlooked for CAR T therapy."
Clinical • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Infectious Disease • Inflammation • Multiple Myeloma
|
|
Doris Hansen1; Othman S. Akhtar2; Ajay K. Nooka3; Surbhi Sidana4; Krina Patel5; Marcelo C. Pasquini2; Sophie Hello6; Maryna Levikova6; Romain Piault6; Devender S. Dhanda6; Omar Nadeem7
|